Which has better earnings & valuation, STOK or QGEN?

Qiagen has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stoke Therapeutics $184.42M 9.95 -$6.89M -$2.81 N/A Qiagen $2.09B 3.59 $424.88M $1.91 19.08

Is STOK or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Stoke Therapeutics' net margin of -529.20%. Qiagen's return on equity of 14.40% beat Stoke Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Stoke Therapeutics -529.20% -48.84% -42.27% Qiagen 19.16% 14.40% 8.40%

Does the media favor STOK or QGEN?

In the previous week, Qiagen had 14 more articles in the media than Stoke Therapeutics. MarketBeat recorded 18 mentions for Qiagen and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Qiagen's score of -0.43 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor STOK or IMVT?

In the previous week, Immunovant had 4 more articles in the media than Stoke Therapeutics. MarketBeat recorded 8 mentions for Immunovant and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Immunovant's score of 0.35 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor STOK or PCVX?

In the previous week, Vaxcyte had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Vaxcyte's score of 0.31 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LNTH or STOK more profitable?

Lantheus has a net margin of 18.05% compared to Stoke Therapeutics' net margin of -529.20%. Lantheus' return on equity of 29.32% beat Stoke Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Stoke Therapeutics -529.20% -48.84% -42.27%

Does the media refer more to LNTH or STOK?

In the previous week, Lantheus had 1 more articles in the media than Stoke Therapeutics. MarketBeat recorded 5 mentions for Lantheus and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Lantheus' score of 0.44 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STOK or KYMR?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Kymera Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Kymera Therapeutics' score of 0.64 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Stoke Therapeutics (STOK) Competitors

$29.46 +0.78 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$29.40 -0.05 (-0.19%)

As of 04:38 PM Eastern

Compare

STOK vs. QGEN, IMVT, PCVX, LNTH, and KYMR

Should you buy Stoke Therapeutics stock or one of its competitors? MarketBeat compares Stoke Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stoke Therapeutics include Qiagen (QGEN), Immunovant (IMVT), Vaxcyte (PCVX), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Stoke Therapeutics compare to Qiagen?

Stoke Therapeutics (NASDAQ:STOK) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Stoke Therapeutics currently has a consensus price target of $41.83, indicating a potential upside of 42.00%. Qiagen has a consensus price target of $44.98, indicating a potential upside of 23.41%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Stoke Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Qiagen has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Qiagen	$2.09B	3.59	$424.88M	$1.91	19.08

Qiagen has a net margin of 19.16% compared to Stoke Therapeutics' net margin of -529.20%. Qiagen's return on equity of 14.40% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Qiagen	19.16%	14.40%	8.40%

Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Qiagen had 14 more articles in the media than Stoke Therapeutics. MarketBeat recorded 18 mentions for Qiagen and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Qiagen's score of -0.43 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Stoke Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Stoke Therapeutics compare to Immunovant?

Stoke Therapeutics (NASDAQ:STOK) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Stoke Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Immunovant has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Immunovant	N/A	-65.66%	-59.88%

In the previous week, Immunovant had 4 more articles in the media than Stoke Therapeutics. MarketBeat recorded 8 mentions for Immunovant and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Immunovant's score of 0.35 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.1% of Immunovant shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Stoke Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Stoke Therapeutics currently has a consensus target price of $41.83, indicating a potential upside of 42.00%. Immunovant has a consensus target price of $37.33, indicating a potential upside of 19.85%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Stoke Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Stoke Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Vaxcyte?

Stoke Therapeutics (NASDAQ:STOK) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Stoke Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Vaxcyte's return on equity of -32.51% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Vaxcyte had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Vaxcyte's score of 0.31 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics has higher revenue and earnings than Vaxcyte. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

96.8% of Vaxcyte shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Stoke Therapeutics presently has a consensus price target of $41.83, indicating a potential upside of 42.00%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 83.25%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Vaxcyte beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Lantheus has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.16
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A

Lantheus currently has a consensus target price of $101.86, suggesting a potential upside of 1.60%. Stoke Therapeutics has a consensus target price of $41.83, suggesting a potential upside of 42.00%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Stoke Therapeutics' net margin of -529.20%. Lantheus' return on equity of 29.32% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

In the previous week, Lantheus had 1 more articles in the media than Stoke Therapeutics. MarketBeat recorded 5 mentions for Lantheus and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Lantheus' score of 0.44 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Stoke Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Kymera Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Stoke Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

Stoke Therapeutics currently has a consensus price target of $41.83, suggesting a potential upside of 42.00%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 61.38%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Stoke Therapeutics has a net margin of -529.20% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Kymera Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.18 beat Kymera Therapeutics' score of 0.64 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Kymera Therapeutics	$39.21M	153.52	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Stoke Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-10.48	9.91	18.89	22.53
Price / Sales	9.95	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	4.77	6.63	9.84	6.72
Net Income	-$6.89M	$24.20M	$3.57B	$337.19M
7 Day Performance	-6.33%	-3.24%	-1.16%	0.48%
1 Month Performance	-10.94%	0.53%	3.85%	5.07%
1 Year Performance	170.28%	47.24%	27.40%	34.25%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	3.0505 of 5 stars	$29.46 +2.7%	$41.83 +42.0%	+189.4%	$1.79B	$184.42M	N/A	100	Positive News Gap Up
QGEN Qiagen	4.1509 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-24.4%	$7.25B	$2.09B	18.40	5,654
IMVT Immunovant	2.3558 of 5 stars	$34.15 flat	$35.33 +3.5%	+100.6%	$7.01B	N/A	N/A	120	Gap Up
PCVX Vaxcyte	2.7424 of 5 stars	$47.30 flat	$86.00 +81.8%	+35.4%	$6.83B	N/A	N/A	160	Insider Trade
LNTH Lantheus	2.4079 of 5 stars	$103.00 flat	$99.71 -3.2%	+24.9%	$6.71B	$1.54B	24.82	1,193	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. QGEN, IMVT, PCVX, LNTH, and KYMR

How does Stoke Therapeutics compare to Qiagen?

Summary

How does Stoke Therapeutics compare to Immunovant?

Summary

How does Stoke Therapeutics compare to Vaxcyte?

Summary

How does Stoke Therapeutics compare to Lantheus?

Summary

How does Stoke Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. QGEN, IMVT, PCVX, LNTH, and KYMR

How does Stoke Therapeutics compare to Qiagen?

Do analysts rate STOK or QGEN?

Which has better earnings & valuation, STOK or QGEN?

Is STOK or QGEN more profitable?

Which has more volatility & risk, STOK or QGEN?

Do institutionals and insiders have more ownership in STOK or QGEN?

Does the media favor STOK or QGEN?

Summary

How does Stoke Therapeutics compare to Immunovant?

Which has higher valuation & earnings, STOK or IMVT?

Is STOK or IMVT more profitable?

Does the media favor STOK or IMVT?

Do insiders and institutionals have more ownership in STOK or IMVT?

Which has more risk and volatility, STOK or IMVT?

Do analysts rate STOK or IMVT?

Summary

How does Stoke Therapeutics compare to Vaxcyte?

Which has more risk & volatility, STOK or PCVX?

Is STOK or PCVX more profitable?

Does the media favor STOK or PCVX?

Which has preferable earnings and valuation, STOK or PCVX?

Do insiders & institutionals have more ownership in STOK or PCVX?

Do analysts rate STOK or PCVX?

Summary

How does Stoke Therapeutics compare to Lantheus?

Which has more volatility and risk, LNTH or STOK?

Which has better earnings and valuation, LNTH or STOK?

Do analysts prefer LNTH or STOK?

Do institutionals and insiders have more ownership in LNTH or STOK?

Is LNTH or STOK more profitable?

Does the media refer more to LNTH or STOK?

Summary

How does Stoke Therapeutics compare to Kymera Therapeutics?

Which has more volatility & risk, STOK or KYMR?

Do analysts rate STOK or KYMR?

Is STOK or KYMR more profitable?

Does the media favor STOK or KYMR?

Which has preferable valuation & earnings, STOK or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools